Where The COVID Vaccine Trials Stand: A Snapshot Of The Leaders And Rest Of The Field
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an inflection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
You may also be interested in...
With strong data from Moderna and Pfizer, the projection for an EUA by the end of 2020 still may hold despite holidays and other obstacles to completing the necessary work.
Sponsors are moving to younger populations as the adult clinical trials near enrollment goals; Moderna’s CEO says data in children younger than 12 will be slow to emerge.
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.